Rituximab in severe, treatment‐refractory interstitial lung disease
Respirology2013Vol. 19(3), pp. 353–359
Citations Over TimeTop 1% of 2013 papers
Gregory J. Keir, Toby M. Maher, Damien Ming, Reza Abdullah, Angelo De Lauretis, M. Wickremasinghe, Andrew G. Nicholson, David M. Hansell, Athol U. Wells, Elisabetta Renzoni
Abstract
In patients with severe, progressive non-IPF ILD unresponsive to conventional immunosuppression, rituximab may offer an effective therapeutic intervention. Future prospective, controlled trials are warranted to validate these findings, and to assess safety outcomes.
Related Papers
- → Common idiopathic pulmonary fibrosis risk variants are associated with hypersensitivity pneumonitis(2022)32 cited
- → Pulmonary Function in Diffuse Sarcoidosis(1974)20 cited
- → Comparison of Single-Breath and Intra-Breath Method inMeasuring Diffusing Capacity for Carbon Monoxide of the Lung(1995)
- → Decline in forced vital capacity (FVC) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) with and without cough: data from the SENSCIS trial*(2022)
- → Long-term Safety Data of Inhaled Pirfenidone (AP01) in Idiopathic Pulmonary Fibrosis (IPF) and Non-IPF Interstitial Lung Disease (ILD) Patients(2023)